Copyright
©The Author(s) 2019.
World J Hepatol. Jun 27, 2019; 11(6): 531-541
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.531
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.531
Figure 2 Kaplan-Meir survival curves.
A: Results from log-rank test showed significant differences in Child-Pugh A and B vs Child-Pugh C. a: Survival data of patients with Child-Pugh A and B (n = 30), b: Survival data of patients with Child-Pugh C (n = 8). Median survival time was 43 wk; B: Results from log-rank test showed no significant differences of rifaximin group vs control group. a: Survival data of rifaximin group (n = 38), b: Survival data of control group (n = 34).
- Citation: Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, Horikawa Y, Shiwa Y, Saitoh S. Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. World J Hepatol 2019; 11(6): 531-541
- URL: https://www.wjgnet.com/1948-5182/full/v11/i6/531.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i6.531